EnteroBiotix, a Glasgow-based biotech firm specialising in full-spectrum microbiome therapeutics, announced that it has closed a funding round totalling £27M (approximately €31.46M).
EnteroBiotix’s financing includes £15.7M (approximately €18.29M) in fresh equity and the conversion of £11.6M (approximately €13.51M) of loan notes into equity.
The investment comes from both new and existing investors, furthering the company’s progress in the clinical-stage development of its microbiome therapies.
Contributors to this funding round are US-based life science investors Thairm Bio and Kineticos Life Sciences, along with support from the Scottish National Investment Bank.
Additionally, existing investors such as Scottish Enterprise and several private investors of the company have also participated in this funding initiative.
A microbiome therapeutics platform
Founded in 2017, EnteroBiotix is a clinical-stage biopharmaceutical company focused on developing “best-in-class” full-spectrum microbial therapeutics for patients facing significant unmet medical needs.
Leveraging its product platform, the company aims to address patient requirements through a pipeline of customised, “high-diversity” products designed to fortify and restore the microbiome.
EnteroBiotix has forged a strategic partnership with Imperial College London to facilitate clinical trials in critical, unmet medical areas.
Recently, the company announced the commencement of a Phase 2 clinical trial targeting Irritable Bowel Syndrome (IBS). Additionally, EnteroBiotix has concluded patient enrollment in a Phase 2 clinical study focusing on liver cirrhosis.
EnteroBiotix boasts advanced platform manufacturing technologies and an analytical toolkit, resulting in superior product characteristics. With MHRA-licensed manufacturing infrastructure, and its Number 2® brand, the company ensures safety, security, quality, and ample supply of microbiota sourced from healthy human donors.
Currently, the company operates research laboratories and MHRA-licensed GMP pharmaceutical manufacturing sites in Glasgow and Aberdeen.
Capital utilisation
EnteroBiotix plans to use the funds to propel the development of its primary product candidate, EBX-102-02, through a Phase 2 clinical trial focused on Irritable Bowel Syndrome (IBS), conducted in collaboration with the Functional Gut Clinic.
Additionally, the funding will support the advancement of its pipeline targeting various conditions associated with a disrupted gut microbiome, such as liver cirrhosis and hepatic encephalopathy (HE).
Dr James McIlroy, CEO of EnteroBiotix, says, “This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome.”
“It will help accelerate the development of our innovative product pipeline and propel us towards our goal of bringing these innovative treatments to market.”
“We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe,” adds McIlroy.
Brief about Irritable Bowel Syndrome (IBS)
IBS is a chronic gastrointestinal disorder marked by symptoms like abdominal pain, cramping, bloating, and altered bowel movements, including constipation, diarrhoea, or both.
According to a press release by EnteroBiotix, it affects approximately one in eight individuals, with an equal split between constipation-dominant (IBS-C) and diarrhoea-dominant (IBS-D) cases. The condition carries a substantial healthcare and economic burden.
About The Functional Gut Clinic
The Functional Gut Clinic (FGC) is the UK’s independent provider of gastrointestinal physiology testing and diagnostics, serving both private and NHS patients nationwide.
FGC holds accreditations, including IQIPS/UKAS and CQC. Since its establishment in 2013, FGC has built a robust R&D and clinical trials portfolio, contributing to the development and assessment of future digestive health tests and treatments.
01
Beyond parental controls: How Rotterdam’s ChatLicense empowers kids in the digital age